Hybrid09/06/2022

EHA Congress

European Hematology Association

Join us for the 2022 edition of the European Hematology Association (EHA) Congress


Octapharma is supporting the #EHA2022 Hybrid Congress to keep the scientific community up to date on treating patients with secondary immunodeficiencies associated with hematological malignancies.

Octapharma Update-in-Hematology

Innovative approaches to reduce the infection burden in hematological malignancies

Friday 10th of June 18:00 - 19:00 CET

Programme

Speaker

Welcome and introduction

Chair: Tadeusz Robak (Lodz, Poland)

The burden of COVID-19 in patients with CLL

Lydia Scarfò (Milan, Italy)

Unlocking the risk of infection in CLL with epidemiology, clinical observations and machine learning

Christian Brieghel (Copenhagen, Denmark)

Uncovering patients’ infection risk in lymphoma and associated treatments including CAR-T cell therapy

Vincent Camus (Rouen, France)

Real-world evidence leveraging the use of immunoglobulin replacement therapy in hematological malignancies

Fabrizio Vianello (Padua, Italy)

Panel discussion – Q&A

All

Closing

Tadeusz Robak (Lodz, Poland)

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.

Speakers panel

Chair: Tadeusz Robak

Copernicus Memorial Hospital

Medical University of Lodz, Poland

Lydia Scarfò

Vita-Salute San Raffaele

University of Milan, Italy

Christian Brieghel

Rigshospitalet, Copenhagen,

Denmark

Fabrizio Vianello

University of Padua,

Italy

Vincent Camus

Centre Henri Becquerel,

Rouen, France

Visit our website to learn more about SID

"Secondary immunodeficiencies have been a major concern in hematological malignancies. We need to remain very careful with the risk of infection.", says Dr. Anne Quinquenel (Reims, France).

Discover more on hematological malignancies

Octapharma's exclusive educational platform for healthcare professionals.